Please note that following on from information provided to NICE by the company in October 2022, the appraisal of "1645 - Obeticholic acid for treating liver fibrosis in people with steatohepatitis "was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | Dear stakeholders, As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| Process | TA |
| ID number | 4068 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 30 October 2024 | Discontinued. Please note that following on from information provided to NICE by the company in October 2022, the appraisal of "1645 - Obeticholic acid for treating liver fibrosis in people with steatohepatitis "was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 14 October 2022 | Suspended. As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual